Orexigen Therapeutics (OREX) Reports Q2 Loss of $2.00/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts OREX Hot Sheet
Price: $0.22 --0%
Financial Fact:
Research and development: 5.25M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Research and development: 5.25M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Orexigen Therapeutics (NASDAQ: OREX) reported Q2 EPS of ($2.00), versus ($1.73) reported last year. Revenue for the quarter came in at $23.4 million versus the consensus estimate of $19.14 million.
For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- XPEL, Inc. (XPEL) Tops Q3 EPS by 4c, Misses on Revenue; Offers Q4 Revenue Guidance
- Datadog stock tumbles 19% despite earnings beat
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
